SBRT2015

Metastatic melanoma – phase III trial

Larkin J, NEJM 2015

Progression-free survival

Median PFS

11.5

months with nivolumab plus ipilimumab, as

compared with

2.9

months with ipilimumab and

6.9

months with

nivolumab (HR for comparison with ipilimumab, 0.57; 99.5% CI, 0.43

to 0.76; P<0.001)